Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Galapagos NV ADR

GXEA
Current price
25 EUR 0 EUR (0.00%)
Last closed 27 USD
ISIN US36315X1019
Sector Healthcare
Industry Biotechnology
Exchange Stuttgart Exchange
Capitalization 1 777 281 024 USD
Yield for 12 month -25.18 %
1Y
3Y
5Y
10Y
15Y
GXEA
21.11.2021 - 28.11.2021

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. Address: Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

30.63 USD

P/E ratio

Dividend Yield

Current Year

+260 723 449 USD

Last Year

+549 541 740 USD

Current Quarter

+84 694 553 USD

Last Quarter

+84 694 553 USD

Current Year

+260 697 346 USD

Last Year

+536 404 639 USD

Current Quarter

+66 687 186 USD

Last Quarter

+66 687 187 USD

Key Figures GXEA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -136 034 752 USD
Operating Margin TTM -90.74 %
PE Ratio
Return On Assets TTM -2.38 %
PEG Ratio
Return On Equity TTM -2.21 %
Wall Street Target Price 30.63 USD
Revenue TTM 260 094 000 USD
Book Value 43.41 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -50.1 %
Dividend Yield
Gross Profit TTM 4 818 000 USD
Earnings per share -1 USD
Diluted Eps TTM -1 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY 74.8 %
Profit Margin 79.33 %

Dividend Analytics GXEA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History GXEA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation GXEA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 166.6667
Enterprise Value Revenue 1.1836
Price Sales TTM 6.8332
Enterprise Value EBITDA -31.4982
Price Book MRQ 0.5701

Financials GXEA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GXEA

For 52 weeks

24.16 USD 42.46 USD
50 Day MA 29.17 USD
Shares Short Prior Month 1 513 170
200 Day MA 30.07 USD
Short Ratio 14.21
Shares Short 1 516 067
Short Percent 3.08 %